Paid 8 min read
MDT — pipeline value the Street ignores
Subscribers get the full thesis, the levels, and my positioning on MDT. Subscribe to read on.
Subscribers get the full thesis, the levels, and my positioning on MDT. Subscribe to read on.
Subscribers get the full thesis, the levels, and my positioning on MRNA. Subscribe to read on.
Subscribers get the full thesis, the levels, and my positioning on VRTX. Subscribe to read on.
The risk/reward into the readout is asymmetric if you size the basket right.